Dova Pharmaceuticals Inc (NASDAQ:DOVA) has been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $32.25.

Several equities analysts have weighed in on the stock. BidaskClub lowered shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 29th. Evercore ISI assumed coverage on shares of Dova Pharmaceuticals in a report on Friday, March 23rd. They issued a “line” rating and a $29.00 target price on the stock.

How to Become a New Pot Stock Millionaire

NASDAQ:DOVA opened at $26.17 on Tuesday. The stock has a market capitalization of $736.75 and a price-to-earnings ratio of -18.69. Dova Pharmaceuticals has a 1-year low of $16.98 and a 1-year high of $37.00.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Thursday, February 15th. The company reported ($0.36) earnings per share for the quarter, meeting the consensus estimate of ($0.36). During the same quarter last year, the business earned ($0.44) earnings per share. equities research analysts predict that Dova Pharmaceuticals will post -1.45 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its holdings in Dova Pharmaceuticals by 702.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock valued at $137,000 after purchasing an additional 4,163 shares during the last quarter. Deutsche Bank AG boosted its holdings in Dova Pharmaceuticals by 139.2% in the 4th quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock valued at $337,000 after purchasing an additional 6,836 shares during the last quarter. California State Teachers Retirement System acquired a new position in Dova Pharmaceuticals in the 3rd quarter valued at about $202,000. Geode Capital Management LLC boosted its holdings in Dova Pharmaceuticals by 18.1% in the 4th quarter. Geode Capital Management LLC now owns 62,359 shares of the company’s stock valued at $1,795,000 after purchasing an additional 9,566 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in Dova Pharmaceuticals in the 3rd quarter valued at about $241,000. Institutional investors own 26.05% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Dova Pharmaceuticals Inc (DOVA) Receives Average Rating of “Hold” from Brokerages” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/04/16/dova-pharmaceuticals-inc-dova-receives-average-rating-of-hold-from-brokerages.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.